logo
India's Luxury Hotels Are Underpriced, That Must Change, Says Oberoi CEO

India's Luxury Hotels Are Underpriced, That Must Change, Says Oberoi CEO

Skift26-05-2025

According to Vikram Oberoi, it's time Indian hotels stopped selling themselves short. He's betting that Indian guests are ready to pay more, especially for top-tier stays.
Luxury hotels in India are 'significantly underpriced,' according to Vikram Oberoi, managing director, CEO and executive director of EIH Limited.
Oberoi said he's keen to change that.
'Our objective is to drive our rates higher, and we've done that during the financial year, and we'll continue to do that going forward,' Oberoi said during the company's earnings call on Monday. EIH Limited operates the Oberoi and Trident hotel brands.
Oberoi even suggested the company would rather sacrifice some occupancy if that means stronger pricing. 'If demand continues to be as it is today, our endeavor will be to drive rates up to the largest extent possible, and even if that is at the cost of occupancy. As long as our RevPAR sees strong growth, and I don't see any reason why that will change.'
This marks a shift in focus from just filling rooms to making each room night more valuable.
He argued that room prices in India's top cities, Delhi, Mumbai and Bengaluru, are well below what the quality justifies, especially compared to global peers.
He didn't mince words: 'You can go online and see top hotels around the world in key cities. A good hotel costs $1,000 upwards per night. We are significantly below that threshold. And if I then combine that with the quality of hotels we have in India, in our key cities, I think there's tremendous opportunity for upside in average room rate.'
Financial Performance Highlights
EIH's financial results back Oberoi's confidence. The company delivered its best-ever performance. EIH reported a 13% year-on-year increase in consolidated EBITDA to INR 11.5 billion ($135 million) for fiscal 2025. Net profit rose by 14% to INR 7.7 billion ($90 million). Revenue from operations grew 9% on a standalone basis to INR 25.35 billion ($298 million) and 10% to INR 28.8 billion ($338 million) at the consolidated level.
In the fourth quarter alone, RevPAR (revenue per available room) rose 22% year-on-year across all domestic hotels. Oberoi-owned hotels led the way, with a 24% rise in RevPAR, outpacing the industry average of 16% and even edging out Trident's 22% growth.
Occupancy also climbed from 81% last year to 84%.
While international operations contributed a smaller share, the growth reported was healthy, with a 10% rise in revenue and a similar growth in EBITDA.
Betting on India's Premium Travel Upsurge
Oberoi's bullish outlook is also rooted in structural changes in India's economy. 'There's an opportunity to push rates higher, especially with India's rising affluence and growing demand for quality accommodation,' he said.
Oberoi also cited the 'significant changes' taking place in the Indian economy. With increasing wealth and affluence there's a desire for quality accommodation and quality hotels that provide exceptional services and experiences to guests, he said.
Ultra high-net worth individuals, those with a net worth of $30 million and above, in India grew by 11% last year, according to industry reports cited in the company's presentation. Oberoi sees this as a key demand driver, especially in the luxury leisure segment.
Domestic travel is also on the rise. The fourth quarter saw air traffic grow 9% year-on-year. Inbound tourism is projected to rise by 15% in fiscal 2026, buoyed by India's improving global profile and infrastructure upgrades.
Coming Up: 21 New Hotels
EIH isn't just raising prices, it's also growing its footprint. The company plans to add 21 new properties (roughly 1,500 rooms) over the next 3-4 years. Of these, 12 are in India.
EIH's expansion plan includes nine international projects, including cruise ships. Two luxury boats will debut this year, including a Nile cruiser by 2026, alongside properties in Egypt, Nepal, Bhutan and Saudi Arabia.
Upon completion, 16 hotels (including the boats and cruiser) will operate under the Oberoi brand and 5 hotels under the Trident brand, representing a total inventory of approximately 1473 keys.
In India the openings include Goa, Tirupati, Rishikesh and Bengaluru. This includes both managed and owned assets, with Oberoi stating the company is open to acquisitions and brownfield opportunities to accelerate growth.
The group currently operates 4,200 rooms across 30 hotels. Its domestic portfolio includes 3,700 keys, while international properties make up around 500 rooms.
What am I looking at? The performance of hotels and short-term rental sector stocks within the ST200. The index includes companies publicly traded across global markets, including international and regional hotel brands, hotel REITs, hotel management companies, alternative accommodations, and timeshares.
The Skift Travel 200 (ST200) combines the financial performance of nearly 200 travel companies worth more than a trillion dollars into a single number. See more hotels and short-term rental financial sector performance.
Read the full methodology behind the Skift Travel 200.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Stock market today: Dow, S&P 500 and Nasdaq futures rise as stocks set to end June with a bang
Stock market today: Dow, S&P 500 and Nasdaq futures rise as stocks set to end June with a bang

Yahoo

timean hour ago

  • Yahoo

Stock market today: Dow, S&P 500 and Nasdaq futures rise as stocks set to end June with a bang

US stock futures edged higher Sunday evening, setting up the major indexes for more records to end one of the most volatile first halves of a year in recent memory. Futures tied to the Dow Jones Industrial Average (YM=F) rose around 0.5%. Contracts on the S&P 500 (ES=F) gained 0.2%, and Nasdaq 100 (NQ=F) futures ticked up 0.3%. Several of Trump's economic agenda items are in focus this week. A July 9 deadline looms before the possible resumption of Trump's unilateral tariffs, which Trump on Sunday said he didn't think he'd "need to" extend. On the trade front, India has extended its Washington visit to finalize a deal. Administration officials last week confirmed a trade framework with China was in place, bolstering investor sentiment despite a late-Friday dip triggered by Trump's abrupt halt to talks with Canada, citing its digital tax policy. Meanwhile, market watchers are closely following Senate negotiations over Trump's proposed $4.5 trillion tax cut bill. The measure, which passed a procedural vote Saturday, could face a tough path in the House. The Congressional Budget Office estimates it would add $3.3 trillion to the deficit over a decade. For the market, June's gains have been substantial, fueled by optimism surrounding global trade and easing fears over tariffs. The S&P 500 (^GSPC) is up over 4%, the Nasdaq Composite (^IXIC) has surged over 5.5%, and the Dow (^DJI) has climbed 3.5%. On Friday, all three major indexes closed higher, with the S&P and Nasdaq reaching new record highs for the first time since February — the start of the year's tariff-fueled stock swings. All three major indexes are up at least 3% so far this year. Looking ahead, investors will monitor key Chinese PMI data due Monday to gauge how the ongoing trade war is affecting Asia's largest economy. Despite lingering uncertainties, the broader market remains upbeat heading into the new quarter and second half.

Torrent Pharma to Acquire Controlling Stake in J. B. Chemicals & Pharmaceuticals from KKR
Torrent Pharma to Acquire Controlling Stake in J. B. Chemicals & Pharmaceuticals from KKR

Associated Press

time2 hours ago

  • Associated Press

Torrent Pharma to Acquire Controlling Stake in J. B. Chemicals & Pharmaceuticals from KKR

MUMBAI, India--(BUSINESS WIRE)--Jun 29, 2025-- Torrent Pharmaceuticals Limited ('Torrent') and global investment firm KKR today announced that Torrent has entered into definitive agreements to acquire controlling stake in J. B. Chemicals and Pharmaceuticals ('JB Pharma') from KKR at an Equity Valuation of INR 25,689 crores (on fully diluted basis), followed by a merger of the two entities. The transaction marks a significant step in Torrent's ambition to create a future-ready, diversified healthcare platform combining a deep chronic segment heritage with emerging international CDMO capabilities. This press release features multimedia. View the full release here: The transaction will be executed in 2 phases: Samir Mehta, Executive Chairman, Torrent, commented: 'We are pleased to have on board the JB Pharma heritage and build on the platform for the future. Torrent's deep India presence and JB Pharma's fast growing India business, combined with the CDMO and international footprint offers immense potential to scale both revenue and profitability. This strategic alignment furthers our goal of strengthening our presence in the Indian pharma market, and build a larger diversified global presence. Moreover, the CDMO platform provides a new long-term avenue of growth for Torrent.' Gaurav Trehan, Co-Head of Asia Pacific and Head of Asia Pacific Private Equity, KKR, and CEO of KKR India, said: 'JB Pharma's transformation under our stewardship is a testament to KKR's ability to scale high-quality companies. We are proud to have collaborated with JB Pharma's management team, led by Nikhil Chopra, to bring the breadth of KKR's global experience and operational expertise to support the company's organic and inorganic growth, and help JB Pharma become one of India's fastest growing branded pharmaceutical companies. We believe the company is well-positioned for continued growth ahead and wish the team every success in its next chapter with Torrent.' Nikhil Chopra, Chief Executive Officer and Whole Time Director of JB Pharma, remarked: 'Over the past five years, JB Pharma has emerged as one of India's fastest growing pharmaceutical players, owing to KKR's strategic guidance, stewardship of our independent directors and a focused strategic and executional excellence by the management team. We have built a strong foundation to deliver market-leading growth, as well as consistent improvement in profitability in the medium and long term. As we now enter a new chapter alongside Torrent Pharmaceuticals, we are confident that the combined strengths of our organizations will unlock greater opportunities to enhance healthcare access across our markets.' Strategic Rationale for Acquisition Transaction Structure & Approvals View source version on CONTACT: Media ContactsFor KKR: Wei Jun Ong +65 6922 5813 [email protected] Torrent Pharma: Jayesh Desai +91 9824501396 KEYWORD: INDIA ASIA PACIFIC INDUSTRY KEYWORD: FINANCE HEALTH PROFESSIONAL SERVICES PHARMACEUTICAL ASSET MANAGEMENT SOURCE: KKR Copyright Business Wire 2025. PUB: 06/29/2025 11:53 AM/DISC: 06/29/2025 11:53 AM

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store